Form 8-K · Current report
Eli Lilly 8-K, filed Aug 5, 2026
- Filed
- CIK
- 0000059478
- Accession no.
- 0000059478-26-000077
Summary
Eli Lilly reported second-quarter 2026 revenue of $23.0 billion, up 48% from a year earlier, raised full-year 2026 revenue guidance to $85–87 billion, and posted reported EPS of $7.94 (up 26%) and non-GAAP EPS of $8.38 (up 33%), both including $3.03 of acquired IPR&D charges. The company also cited U.S. FDA approval of Ebglyss for an eight-week maintenance dose in moderate-to-severe atopic dermatitis, European Commission approval of Jaypirca as monotherapy for chronic lymphocytic leukemia, and a completed Phase 3 data package for retatrutide in obesity with a planned U.S. Biologics License Application in the first quarter of 2027.
Key points
- Q2 2026 revenue rose 48% to $23.0 billion, driven by Mounjaro and Zepbound volume, with U.S. revenue up 33% to $14.4 billion and revenue outside the U.S. up 80% to $8.6 billion.
- U.S. FDA approved Ebglyss for one maintenance dose every eight weeks in moderate-to-severe atopic dermatitis, and the European Commission approved Jaypirca as monotherapy for adults with chronic lymphocytic leukemia across all lines of therapy.
- Eli Lilly completed the acquisitions of Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals and Kelonia Therapeutics during the quarter and entered an agreement to acquire AtaiBeckley.
- Eli Lilly committed an additional $4.5 billion to expand its Indiana manufacturing sites.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.